The search for an HIV vaccine has been long and difficult, but researchers from Johnson & Johnson, Harvard and other groups may have made a leap. J&J's Janssen reported encouraging results Thursday from its preclinical trial of an HIV vaccine in rhesus monkeys. Encouraging enough for the company to sponsor human studies--the first time a Big Pharma is doing so in the HIV space.
Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) have virtually indistinguishable symptoms, yet each requires a different approach for effective treatment. Now, in what is thought to be the largest functional neuroimaging study to date, researchers have identified biological differences between TBI and PTSD by using single photon emission computed tomography to scan the brain.
Sanofi has re-upped with its partners at Medicines for Malaria Venture in hopes of developing a single-dose treatment for the infectious disease, advancing a pair of candidates through mid-stage development.
Researchers have developed a new technique that could enable an earlier and more accurate identification of the presence of a particular bacteria, virus or fungus even when the infection remains only in the respiratory or gastrointestinal tract.
Partners Merck and Samsung Bioepis cleared late-stage trials with their knockoff of Humira, the world's top-selling medicine, setting the stage for global regulatory applications as the reference treatment comes off patent.
23andMe raked in $79 million of a $150 million round, according to documents filed with the SEC, giving the company a boost as it dials up its R&D efforts.
As physicians turn to mammography as a more reliable way to diagnose breast cancer, a new study shows that the screening method does not reduce the number of deaths from the disease and could lead to overdiagnosis, suggesting a few kinks in the system.
Esperion, at work on a cholesterol-lowering pill it hopes can disrupt some high-profile new injections, convinced the FDA to remove a partial clinical hold on the highest dose of its drug.
Working off of an $80 million crossover round with newly won boasting rights to the FDA's breakthrough therapy designation in hand, Brisbane, CA-based Aimmune Therapeutics is wasting no time in diving into the heated IPO waters for biotech. The biotech filed plans to raise $115 million on Nasdaq, the latest in a scrum of developers anxious to tap into the long-running boom market.
Merck is bowing out of the hectic late-stage scramble to be the first to market with a CGRP migraine drug, handing over its portfolio and two experimental drugs in the pipeline to Allergan for $250 million in cash.